

Asymmetric Synthesis and Biosynthetic Implications of (+)-Fusarisetin A**

Jun Yin, Cheng Wang, Lili Kong, Shujun Cai, and Shuanhu Gao*

The fungal metabolite (+)-fusarisetin A [(+)-**1**; Figure 1], produced by the soil fungus *Fusarium* sp. FN080326, potentially inhibits acinar morphogenesis, cell migration, and cell invasion in MDAMB-231 cells.^[1] Tests of cell growth and cell death using the same cell line showed that (+)-**1** does not exhibit significant cytotoxicity. These findings suggest that (+)-**1** holds promise as a valuable anticancer agent. We aim to develop an efficient synthetic route to enable structure–activity relationship studies of this compound and facilitate the target identification studies. As a first step, we report herein a concise synthesis of (+)-**1** and its potential biosynthetic pathway.





Figure 1. Fusarisetin A [(+)-**1**] and its proposed biosynthetic precursors peroxyfusarisetin (**2**) and equisetin (**3**).

(+)-Fusarisetin A (**1**) possesses unique structural characteristics: 1) a fused pentacyclic ring system (A,B,C,D,E) which contains a *trans* decalin (A,B), a spirokeleton (C,E), and a tetramic acid moiety fused with a tetrahydrofuran ring (D,E); and 2) 10 stereocenters, including two all-carbon quaternary centers (C1, C16). Structurally related natural products possessing tetramic acid rings include equisetin (**3**),^[2] diaphorichalasin,^[3] integramycin,^[4] tirandamycin,^[5] and others.^[6] Recently, Li and co-workers reported the first synthesis of (–)-**1** and revised its absolute configuration.^[7] Theodorakis and co-workers later proposed **3** to be the biosynthetic precursor of **1** and accomplished a biomimetic synthesis of (–)-**1**.^[8]

Equisetin (**3**) is another secondary metabolite isolated from *Fusarium* sp. and contains the basic skeleton (A,B, and E rings) of (+)-**1** but is at a lower oxidation state.^[2] It is reasonable to assume that (+)-**1** is derived from **3** through an oxidative cascade sequence (Scheme 1).^[8] According to this proposed biosynthetic pathway, single-electron oxidation of **3** would give the radical intermediate **5**, which would undergo



Scheme 1. Proposed biosynthetic pathway of (+)-fusarisetin A [(+)-**1**] and equisetin (**3**).

a 5-*exo* cyclization to yield **6**.^[9] Under anaerobic conditions (Pathway A), a second single-electron oxidation would afford **1** via cation **7**. Under aerobic conditions (Pathway B), the radical **6** may trap oxygen to give peroxyfusarisetin (**2**), which could then be reduced to (+)-**1**. The *trans*-decalin unit of **3** is likely produced from the polyene tetramic acid **4** by an intramolecular Diels–Alder reaction (IMDA).^[10] This IMDA strategy was first used by Dixon, Ley, and co-workers to synthesize **3** in 2000,^[2c] and also adopted by Li and co-workers,^[7] as well as Theodorakis and co-workers^[8] to synthesize (–)-**1**.


Guided by this biosynthetic analysis, we developed the synthetic strategy outlined in Scheme 2. We envisioned that preparation of (+)-**1** could be achieved using either the biosynthetic Pathway A or B. The tetramic acid moiety of **3** could be installed through the aminolysis/Dieckmann cyclization of β -keto ester **8** and the (*S*)-serine derivative **9**.^[2d] An

[*] J. Yin,^[†] C. Wang,^[†] L. Kong, S. Cai, Prof. Dr. S. Gao
Shanghai Key Laboratory of Green Chemistry and Chemical
Processes, Department of Chemistry, East China Normal University
3663N Zhongshan Road, Shanghai 200062 (China)
E-mail: shgao@chem.ecnu.edu.cn

[†] These authors contributed equally to this work.

[**] Financial support was provided by the “Yingcai Program” of East China Normal University, the NSFC (21102045), and the Shanghai “Pujiang Program” (11PJ1402800).

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201202455>.




Scheme 2. Retrosynthetic analysis of (+)-fusarisetin A [(+)-1] and equisetin (3).

IMDA/Roskamp reaction could be used to construct the *trans*-decalin **8** from the polyene **10** and ethyl diazoacetate **11**.^[2c,d] In turn, **10** could be easily prepared through Wittig and Horner–Wadsworth–Emmons (HWE) olefinations of **12** with the ylide **13** and phosphonate **14**.

Our synthesis commenced with the preparation of **12** from (+)-citronellal using a previously described two-step procedure (Scheme 3).^[11] Treating **12** with the ylide **13** provided **15** in 91% yield (*E/Z* = 16:1). Removal of the ethylene glycol gave **16**, which was used directly without purification. The HWE olefination of **16** and phosphonate **14**^[2e] converted **16** into triene **17** in 63% yield. The reduction of **17** with DIBAL yielded the allylic alcohol **18**, which was easily oxidized to polyene **10** using Dess–Martin periodinane (DMP). To construct the *trans*-decalin moiety, we extensively surveyed the reaction conditions and found that $\text{BF}_3 \cdot \text{OEt}_2$, Et_2AlCl , or silica gel (during chromatography) promoted the IMDA reaction of **10** with good selectivity (*d.r.* = 9:1). We further found that the Roskamp reaction of the resulting aldehyde **19** and **11** could also be promoted by $\text{BF}_3 \cdot \text{OEt}_2$ in one pot, thus giving **8** in 47% yield over three steps from **18**. Finally, the total synthesis of **3** was completed using the aminolysis and Dieckmann cyclization sequence reported by Danishefsky.^[2d]

We anticipated that **3** would be readily oxidized by single-electron oxidants as it contains a tricarbonyl system which exists as a mixture of keto/enol tautomers. Manganese(III) acetate has been shown to be an effective oxidant for enolizable carbonyl compounds.^[12] The initial application of manganese(III) to oxidative radical cyclizations was reported by Corey and Kang,^[13] Ernst and Fristad,^[14] and Snider and co-workers^[12a,c–g] in the 1980s. To date, radical reactions promoted by manganese(III) have been widely used in organic synthesis, especially natural product synthesis.^[15] We therefore expected that the biomimetic oxidation of **3** could be realized with $\text{Mn}(\text{OAc})_3$ to give (+)-fusarisetin A by either Pathway A or Pathway B.




Scheme 3. Preparation of equisetin (3). Reagents and Conditions:

a) **13** (1.1 equiv), 25 °C, CH_2Cl_2 , 12 h, *E/Z* = 16:1, 91%. b) HCl (1.0 N), 60 °C, 4 h, MeOH. c) **14** (1.3 equiv), LHMDS (1.4 equiv), 30 min, then **16** (1.0 equiv), $-78^\circ\text{C} \rightarrow 25^\circ\text{C}$, 16 h, THF, *E/Z* > 15:1, 63% in 2 steps. d) DIBAL (2.2 equiv), CH_2Cl_2 , -78°C , 3 h, 94%. e) Dess–Martin periodinane (1.5 equiv), H_2O (1.5 equiv), CH_2Cl_2 , 10 min, 25 °C. f) $\text{BF}_3 \cdot \text{OEt}_2$ (3.0 equiv), -78°C , CH_2Cl_2 , 20 min, then **11** (3.0 equiv), 0 °C, 1.5 h, 47% in 3 steps. g) **9** (2.0 equiv), DMAP (2.0 equiv), toluene, 118 °C, 18 h, 68%; h) NaOMe (1.0 equiv), MeOH, 25 °C, 2 h, 72%. i) HF, CH_3CN , 25 °C 2 h, 95%. DIBAL = diisobutylaluminum hydride, DMAP = 4-(dimethylamino)pyridine, LHMDS = lithium hexamethyldisilazide, THF = tetrahydrofuran.

We first found that, under anaerobic conditions, the C ring can be successfully formed by oxidizing **3** with $\text{Mn}(\text{OAc})_3$, but all attempts to induce the formation of the D ring to yield (+)-**1** or trap **6** as an acetate failed (Scheme 4A). The elimination product was obtained as the major product even in the presence of $\text{Cu}(\text{OAc})_2$ or $\text{Yb}(\text{OTf})_3$. For example, oxidation of **3** with $\text{Mn}(\text{OAc})_3$ (2.0 equiv) and $\text{Cu}(\text{OAc})_2$ (5.0 equiv) in degassed HOAc at room temperature gave **21** in 62% yield (*d.r.* = 3.3:1).^[16] On the basis of Snider's mechanistic studies,^[12c–g] we believe that the highly acidic **3** first complexes with $\text{Mn}(\text{OAc})_3$ to form the manganese enolate, which then cyclizes directly to give the radical **6** without the formation of **5**. Oxidation of **6** proceeded through the copper(III) intermediate **7'** to give **21** through a Hofmann elimination with loss of CuOAc and HOAc.^[12c,h–j]

We next found that, under aerobic conditions,^[17] both the C ring and “D ring” can be formed by oxidizing **3** with $\text{Mn}(\text{OAc})_3$ (Scheme 4B). Oxidation of **3** with $\text{Mn}(\text{OAc})_3$ (2.0 equiv) in either air or 1 atm O_2 in HOAc at room temperature gave peroxyfusarisetin (**2**) and 5-*epi*-**2** as inseparable diastereomers in 62% yield (*d.r.* = 1.3:1).^[18] Reduction of **2** and 5-*epi*-**2** with Zn/HOAc furnished (+)-fusarisetin A (**1**) and 5-*epi*-**1**^[7] in a 75% combined yield. The spectroscopic



Scheme 4. Key transformations in the synthesis of (+)-fusarisetin A [(+)-1] from equisetin (**3**) and mechanistic analyses. Reagents and Conditions: a) $\text{Mn}(\text{OAc})_3 \cdot 2\text{H}_2\text{O}$ (2.0 equiv), $\text{Cu}(\text{OAc})_2$ (5.0 equiv), 25°C , degassed HOAc, 2 h, 25°C , d.r. = 3.3:1, 62%. b) $\text{Mn}(\text{OAc})_3 \cdot 2\text{H}_2\text{O}$ (0.1 equiv), air or 1 atm O_2 , 25°C , HOAc, 2 h, then Zn (30.0 equiv), 50°C , 2 h, 41%.

data (^1H and ^{13}C NMR spectra, as well as HRMS, and optical rotation) of synthetic (+)-**1** were fully consistent with the corresponding data for the natural product.^[1]

Mechanistically, this reaction should also proceed through the radical **6**, which is trapped by O_2 instead of $\text{Cu}(\text{OAc})_2$ to give **23** via **22**.^[17] A hydrogen abstraction from **3** then yielded **2** and the radical **5**, which underwent a 5-*exo* cyclization to provide **6** again, thus creating a catalytic cycle. Indeed, we found that oxidation of **3** with 10 mol % $\text{Mn}(\text{OAc})_3$ in either air or O_2 also gave **2** and 5-*epi*-**2** with a comparable 60% yield (d.r. = 1.1:1).^[18] The zinc reduction can be performed in situ to give (+)-**1** directly from **3** in 41% yield. While the enolate of **3** was also involved in the radical initiation step, this aerobic oxidation proceeded mainly through radical **5**, which was not formed in the anaerobic oxidation of **3**. The observation of different diastereoselectivity in the $\text{Mn}^{\text{III}}/\text{Cu}^{\text{II}}$ and $\text{Mn}^{\text{III}}/\text{O}_2$ oxidation reactions is explained by the different intermediates involved in the diastereoselectivity determining step.^[19]

Our synthetic work suggests that the biosynthesis^[20] of (+)-**1** may involve a single-electron transfer (SET) oxidation of **3** to generate **5** and lead to the formation of **2**. The labile peroxy group has been found in the antimalarial natural products artemisinin (Qinghaosu)^[21] and yingzhaosu A^[22] (Figure 2). We suggest that peroxyfusarisetin (**2**) is the biosynthetic intermediate of (+)-**1** and question if the reductive cleavage of the peroxide occurred during its isolation. This one-pot, biomimetic synthesis of (+)-fusarisetin A ((+)-**1**) and peroxyfusarisetin (**2**) from equisetin (**3**)




Figure 2. Structures of artemisinin and yingzhaosu A.

allows us to easily access the natural product(s) for future biological studies. We are particularly interested in examining the antimalarial activity of **2**.

In summary, we have accomplished the first asymmetric synthesis of (+)-fusarisetin A ((+)-**1**). This efficient strategy relies on our proposed biosynthetic pathway involving 1) a one-pot IMDA/Roskamp reaction to construct the *trans*-decalin skeleton, and 2) biosynthetic oxidation of equisetin (**3**) promoted by $\text{Mn}^{\text{III}}/\text{O}_2$. Our synthetic approach has verified the absolute configuration of naturally occurring (+)-**1**, which matches that of its biosynthetic precursor **3**.

Received: March 29, 2012

Revised: May 2, 2012

Published online: June 18, 2012

Keywords: biosynthesis · natural products · peroxides · radical reactions · total synthesis

- [1] J.-H. Jang, Y. Asami, J.-P. Jang, S.-O. Kim, D. O. Moon, K.-S. Shin, D. Hashizume, M. Muroi, T. Saito, H. Oh, B. Y. Kim, H. Osada, J. S. Ahn, *J. Am. Chem. Soc.* **2011**, *133*, 6865–6867.
- [2] For isolation and characterization of equisetin, see: a) H. R. Burmeister, G. A. Bennett, R. F. Vesonder, C. W. Hesseltine, *Antimicrob. Agents Chemother.* **1974**, *5*, 634–639; b) N. J. Phillips, J. T. Goodwin, A. Fraiman, R. J. Cole, D. G. Lynn, *J. Am. Chem. Soc.* **1989**, *111*, 8223–8231; for biosynthesis, see: c) J. W. Sims, J. P. Fillmore, D. D. Warner, E. W. Schmidt, *Chem. Commun.* **2005**, 186–188; for total syntheses, see: d) E. Turos, J. E. Audia, S. J. Danishefsky, *J. Am. Chem. Soc.* **1989**, *111*, 8231–8236; e) L. T. Burke, D. J. Dixon, S. V. Ley, F. Rodríguez, *Org. Lett.* **2000**, *2*, 3611–3613; f) Y. K. Kumiko, M. Shindo, K. Shishido, *Tetrahedron Lett.* **2001**, *42*, 2517–2519; g) L. T. Burke, D. J. Dixon, S. V. Ley, F. Rodríguez, *Org. Biomol. Chem.* **2005**, *3*, 274–280.
- [3] S. Pornpakakul, S. Roengsumran, S. Deechangvipart, A. Petsom, N. Muangsins, N. Ngamrojanavanich, N. Sriubolmas, N. Chaichit, T. Ohta, *Tetrahedron Lett.* **2007**, *48*, 651–655.

- [4] S. B. Singh, D. L. Zink, B. Heimbach, O. Genilloud, A. Teran, K. C. Silverman, R. B. Lingham, P. Felock, D. C. Hazuda, *Org. Lett.* **2002**, *4*, 1123–1126.
- [5] For the isolation of tirandamycins A, B, C, and D, see: a) C. F. Meyer, *J. Antibiot.* **1971**, *24*, 558–560; b) G. F. Crum, W. H. Devries, T. E. Eble, *Arch. Microbiol.* **1976**, *109*, 65–74; c) J. C. Carlson, S. Li, D. A. Burr, D. H. Sherman, *J. Nat. Prod.* **2009**, *72*, 2076–2079.
- [6] For a review of tetramic-acid-type natural products, see: B. J. L. Royles, *Chem. Rev.* **1995**, *95*, 1981–2001.
- [7] J. Deng, B. Zhu, Z.-Y. Lu, H.-X. Yu, A. Li, *J. Am. Chem. Soc.* **2012**, *134*, 920–923.
- [8] J. Xu, E. J. E. Caro-Díaz, L. Trzoss, E. A. Theodorakis, *J. Am. Chem. Soc.* **2012**, *134*, 5072–5075.
- [9] For a review of radical cascade cyclizations, see: A. J. J. McCarroll, C. Walton, *Angew. Chem.* **2001**, *113*, 2282–2307; *Angew. Chem. Int. Ed.* **2001**, *40*, 2224–2248.
- [10] For reviews of the Diels–Alder reaction in total synthesis, see: a) D. Craig, *Chem. Soc. Rev.* **1987**, *16*, 187–238; b) K. C. Nicolaou, S. A. Snyder, T. Montagnon, G. Vassilikogiannakis, *Angew. Chem.* **2002**, *114*, 1742–1773; *Angew. Chem. Int. Ed.* **2002**, *41*, 1668–1698; for a review of IMDA in total synthesis, see: c) K. Takao, R. Munakata, K. Tadano, *Chem. Rev.* **2005**, *105*, 4779–4807.
- [11] Y. Nishikawa, M. Kitajima, N. Kogure, H. Takayama, *Tetrahedron* **2009**, *65*, 1608–1617.
- [12] For reviews of manganese(III)-promoted radical reactions, see: a) B. B. Snider, *Chem. Rev.* **1996**, *96*, 339–364; b) G. G. Melikyan, *Org. React.* **1997**, *49*, 427–520; for a review of the mechanism of Mn(OAc)₃-based radical reactions, see: c) B. B. Snider, *Tetrahedron* **2009**, *65*, 10738–10744; for selected examples of Mn(OAc)₃-promoted radical reactions, see: d) B. B. Snider, J. J. Patricia, S. A. Kates, *J. Org. Chem.* **1988**, *53*, 2137–2143; e) D. P. Curran, T. M. Morgan, C. E. Schwartz, B. B. Snider, M. A. Dombroski, *J. Am. Chem. Soc.* **1991**, *113*, 6607–6617; f) B. B. Snider, B. A. McCarthy, *J. Org. Chem.* **1993**, *58*, 6217–6223; g) B. B. Snider, J. E. Merritt, M. A. Dombroski, B. O. Buckman, *J. Org. Chem.* **1991**, *56*, 5544–5553; for studies of the mechanism of oxidation of radicals by copper(II), see: h) J. K. Kochi in *Free Radicals, Vol. 1* (Ed.: J. K. Kochi), Wiley, New York, **1973**, chap. 11; i) J. K. Kochi, *Acc. Chem. Res.* **1974**, *7*, 351–360; j) B. B. Snider, T. Kwon, *J. Org. Chem.* **1990**, *55*, 1965–1968.
- [13] E. J. Corey, M.-C. Kang, *J. Am. Chem. Soc.* **1984**, *106*, 5384–5385.
- [14] A. B. Ernst, W. E. Fristad, *Tetrahedron Lett.* **1985**, *26*, 3761–3764.
- [15] For selected applications of this reaction to natural product synthesis, see: a) B. B. Snider, Q. Zhang, *J. Org. Chem.* **1993**, *58*, 3185–3187; b) N. H. Vo, B. B. Snider, *J. Org. Chem.* **1994**, *59*, 5419–5423; c) D. Yang, X.-Y. Ye, M. Xu, K.-W. Pang, N. Zou, R. M. Letcher, *J. Org. Chem.* **1998**, *63*, 6446–6447; d) D. Yang, X.-Y. Ye, S. Gu, M. Xu, *J. Am. Chem. Soc.* **1999**, *121*, 5579–5580; e) D. Yang, X.-Y. Ye, M. Xu, K.-W. Pang, K.-K. Cheung, *J. Am. Chem. Soc.* **2000**, *122*, 1658–1663; f) X. Tan, C. Chen, *Angew. Chem.* **2006**, *118*, 4451–4454; *Angew. Chem. Int. Ed.* **2006**, *45*, 4345–4348; g) Z. Ma, J. Lu, X. Wang, C. Chen, *Chem. Commun.* **2011**, *47*, 427–429; h) X. Wang, Z. Ma, J. Lu, X. Tan, C. Chen, *J. Am. Chem. Soc.* **2011**, *133*, 15350–15353.
- [16] The C1, C3, and C6 configurations of *epi*-**21** have not been assigned. For details of the stereochemical analysis, see the Supporting Information.
- [17] For a review of manganese(III)-based peroxidation, see: a) H. Nishino, *Top. Heterocycl. Chem.* **2006**, *6*, 39–76; for selected examples of trapping radical intermediates with O₂, see: b) J. Yoshida, S. Nakatani, S. Isoe, *Tetrahedron Lett.* **1990**, *31*, 2425–2428; c) H. Nishino, S. Tategami, T. Yamada, J. D. Korp, K. Kurosawa, *Bull. Chem. Soc. Jpn.* **1991**, *64*, 1800–1809; d) C. Qian, J. D. Korp, *J. Org. Chem.* **1993**, *58*, 4448–4451; e) A. Boto, R. Hernández, S. M. Velázquez, E. Suárez, *J. Org. Chem.* **1998**, *63*, 4697–4705; f) T. Iwahama, S. Sakaguchi, Y. Ishii, *Chem. Commun.* **2000**, 2317–2318; g) K. Hirase, T. Iwahama, S. Sakaguchi, Y. Ishii, *J. Org. Chem.* **2002**, *67*, 970–973.
- [18] **2** and *5-epi*-**2** were only isolated peroxy diastereomers using Mn^{III}/O₂ conditions. For details of the stereochemical analysis, see the Supporting Information.
- [19] We thank a reviewer for this mechanistic suggestion.
- [20] For reviews of biomimetic syntheses, see: a) S. K. Taylor, *Org. Prep. Proced. Int.* **1992**, *24*, 245–284; b) U. Scholz, E. Winterfeldt, *Nat. Prod. Rep.* **2000**, *17*, 349–366; c) R. A. Yoder, J. N. Johnston, *Chem. Rev.* **2005**, *105*, 4730–4756; d) C. M. Beaudry, J. P. Malerich, D. Trauner, *Chem. Rev.* **2005**, *105*, 4757–4778; e) E. Brunoldi, M. Luparia, A. Porta, G. Zanon, G. Vidari, *Curr. Org. Chem.* **2006**, *10*, 2259–2282; f) P. G. Bulger, S. K. Bagal, R. Marquez, *Nat. Prod. Rep.* **2008**, *25*, 254–297; g) M. Rrazzak, J. K. De Brabander, *Nat. Chem. Biol.* **2011**, *7*, 865–875.
- [21] For isolation and biological activity of artemisinin, see: a) J. M. Liu, M. Y. Ni, J. F. Fen, Y. Y. Tu, Z. H. Wu, Y. L. Wu, W. S. Zhou, *Huaxue Xuebao* **1979**, *37*, 129–141; b) D. L. Klayman, A. J. Lin, N. Acton, J. P. Scovill, J. M. Hoch, W. K. Milhous, A. D. Theoharides, A. S. Dobek, *J. Nat. Prod.* **1984**, *47*, 715–717; c) D. L. Klayman, *Science* **1985**, *228*, 1049–1055; d) R. K. Haynes, S. C. Vonwiller, *Acc. Chem. Res.* **1997**, *30*, 73–79; e) H. Ziffer, R. J. Highet, D. L. Klayman, *Prog. Chem. Org. Nat. Prod.* **1997**, *72*, 121–214; f) Y. Li, Y.-L. Wu, *Médecine Tropicale* **1998**, *58*(Suppl. 3), 9–12, and references therein.
- [22] For the isolation of yingzhaosu, see: L. Zhang, W.-S. Zhou, X. X. Xu, *J. Chem. Soc. Chem. Commun.* **1988**, 523–524.